Detalhe da pesquisa
1.
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Cell Metab
; 7(1): 68-78, 2008 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-18177726
2.
Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Br J Clin Pharmacol
; 74(1): 116-24, 2012 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-22243494
3.
Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial.
EBioMedicine
; 82: 104138, 2022 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-35809371
4.
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Cell Metab
; 4(4): 275-82, 2006 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-17011500
5.
Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.
J Med Chem
; 64(18): 13215-13258, 2021 09 23.
Artigo
Inglês
| MEDLINE | ID: mdl-34375108
6.
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
J Clin Pharmacol
; 49(1): 80-7, 2009 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-19004846
7.
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Br J Clin Pharmacol
; 68(4): 535-45, 2009 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-19843057
8.
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
Lancet
; 370(9603): 1907-14, 2007 Dec 08.
Artigo
Inglês
| MEDLINE | ID: mdl-18068514
9.
Whole-body biodistribution and radiation dosimetry of the human cannabinoid type-1 receptor ligand 18F-MK-9470 in healthy subjects.
J Nucl Med
; 49(3): 439-45, 2008 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-18287275
10.
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
J Clin Pharmacol
; 48(4): 418-27, 2008 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-18258750
11.
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
J Clin Pharmacol
; 48(6): 734-44, 2008 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-18508950
12.
[The fast eating syndrome. A clinical study group offers preventive interventions]. / Le syndrome du mangeur rapide. Un groupe de travail clinique propose des interventions pour le prévenir.
Perspect Infirm
; 10(3): 33-6, 2013.
Artigo
Francês
| MEDLINE | ID: mdl-23705279
13.
Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects.
J Clin Pharmacol
; 58(12): 1578-1585, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30029292
14.
Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects.
J Clin Pharmacol
; 58(2): 254-262, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-28884824
15.
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
J Clin Pharmacol
; 47(2): 165-74, 2007 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-17244767
16.
The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin.
J Clin Pharmacol
; 47(5): 620-7, 2007 May.
Artigo
Inglês
| MEDLINE | ID: mdl-17442687
17.
Effect of sitagliptin on the pharmacokinetics of simvastatin.
J Clin Pharmacol
; 49(4): 483-8, 2009 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-19204138
18.
Pharmacokinetics of etoricoxib in patients with hepatic impairment.
J Clin Pharmacol
; 43(10): 1136-48, 2003 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-14517196
19.
Pharmacokinetics of etoricoxib in patients with renal impairment.
J Clin Pharmacol
; 44(1): 48-58, 2004 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-14681341
20.
Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib.
J Clin Pharmacol
; 54(11): 1247-55, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24782116